• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    PCI Pharma Services

    Aphena Pharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Cytovance Biologics

    PCI Pharma Services

    Aphena Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    AI in Pharma: Transforming Data into Drugs

    Jane Z. Reed of Linguamatics discusses the potential benefits and obstacles leveraging data through AI

    AI in Pharma: Transforming Data into Drugs
    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Regis Custom Pharma
    • Adare Pharma Solutions
    Kristin Brooks, Contract Pharma01.25.19
    With the amount of time and the R&D costs associated with bringing drugs to market, greater efficiency, better processes and analysis are needed for innovation in the pharma and biopharma industry. Artificial Intelligence offers tremendous potential across the drug development continuum, however there are obstacles to overcome in order to benefit from numerous advances in science and technology. Leveraging the massive amounts of data unearthed in drug discovery, development and clinical trials may be key to selecting and advancing the right drug candidates.

    Several AI collaborations among top pharma companies are currently underway. For example, Johnson & Johnson partnered with IBM’s Watson Health for its AI cloud-based system capable of processing high volumes of data and offering evidence-based answers. Pfizer is leveraging the Watson for Drug Discovery cloud-based platform in an effort to help discover new drug targets and alternative drug indications, and Novartis partnered with IBM Watson Health to develop a cognitive solution using real-time data to gain better insights on the expected outcomes of breast cancer treatment options. Furthermore, Genentech, a member of the Roche group, is collaborating with GNS Healthcare to use machine learning to convert high volumes of cancer patient data into computer models that can be used to identify novel targets.

    Based on its recent analysis of the global natural language processing (NLP) in life sciences Artificial Intelligence (AI) market, Frost & Sullivan recently recognized Linguamatics for its I2E NLP text mining platform. This intelligent solution generates insights from a wide range of unstructured and semi-structured data, helping clients to efficiently integrate AI into their operations.

    In its analysis, Frost & Sullivan noted the flexibility of the I2E platform, which can be applied across a variety of applications such as gene-disease mapping and target identification, biomarker discovery, regulatory compliance management, drug safety, clinical trial analysis, drug patent landscape reporting and analysis, real-world data analysis, and identification of clinical care gaps. The solution is currently being used by 18 of the top 20 pharmaceutical companies and numerous oncology research organizations.

    Jane Z. Reed, Ph.D. head of life science strategy at Linguamatics’ discusses the potential benefits and obstacles leveraging data through AI.

    Contract Pharma: What aspects of the drug development continuum have the potential to benefit from AI?

    Jane Z. Reed:
    There’s real potential for AI to impact the whole bench-to-bedside continuum. AI in early research isn’t new. Algorithms for sequence manipulation (BLAST, Clustal), methods in computational chemistry and QSAR, or Bayesian clustering for lead compound or lead series design – these have all been used for years. But one of the core prerequisites for good AI is good data; and previously other areas in drug development have not had suitable data types and data volumes, to provide the substrate for AI technologies. That’s all changing, we have tsunamis of data available – genomic, genetic, real world data from wearables, literature, patents, clinical and more. We now have more data than the human brain could interpret in a lifetime. The move to digital transformation, changing processes to be data-driven rather than document-driven, means that algorithms can be applied to search for patterns, for significance, for many applications.

    That said, one of the hot spots for pharma is utilizing real world data. Data from healthcare records can be accessed better using AI text mining, such as natural language processing, to extract features for machine learning models for risk management, safety alerts, or patient monitoring during clinical trials. These data can be combined with information from wearables, individual genetic data, and more, to better understand patient responses and/or cohort selection, and hence improve clinical trial efficiencies or reduce attrition.

    CP: What are some of the current obstacles with AI in the pharmaceutical industry? How can they be overcome?

    JR:
    There is a huge amount of hype currently around AI, and this can bring pressures for companies or teams to set up an AI project without fully understanding the problem space. Obstacles to a successful project include: not defining a clear problem statement; not having suitable data (too small a data set, too dirty; or locked in data silos); or also, not having good communication between the business user and the IT/IS/data science teams.

    Where we have seen successful implementation of natural language processing (NLP), for example, is where a team can identify a clear and specific problem that is causing a block or challenge within the business (obviously around unstructured text, for NLP applications); define and scope a pilot project to test this; work closely with the business users to understand their needs; and in this way address a practical use case and demonstrate value. Experimenting rapidly and then scaling up successes is a great way to test any new approach. This way, you can gain understanding, and trust of the AI technology, and then build from there.

    CP: Where do you see the most opportunities for AI?

    JR:
    As I said above, making sense of all the structured and unstructured real world data (e.g. electronic heath records) and combining this with genetic and genomic data, is really going to impact how we can design, run and monitor clinical trials.  There’s also significant potential value for AI earlier in drug development, in early discovery. Here, combining information from literature, genomics and genetics, biological assay databases and more, can deepen our understanding of the basic biology of targets, pathways, diseases; and thus improve target selection, target prioritization, biomarker discovery. Currently nine out of ten candidate drugs fail between Phase I clinical trials and regulatory approval, and lack of efficacy is a major concern; often coming down to failure in understanding the fundamental natural history of the disease.

    Several big pharma companies have announced projects with AI or Machine Learning (ML) technologies to address these challenges (e.g. Pfizer is using IBM Watson to improve the search for immuno-oncology agents), and it will be interesting to see how these initiatives progress. We are probably still some years away from the first approved drug discovered by artificial intelligence; but the combination of AI technologies and the human brain (“augmented intelligence”) is already showing signs of accelerating many parts of the drug discovery and development pipeline.

    CP: What does leveraging data through AI entail?

    JR:
    Data can tell a story, but only if you can listen. In order to leverage big data, you need to find it, have access, ensure the data can map to suitable identifiers or standards for integration with other data sets; and only then you can apply algorithms to start analysing the data. Data silos within pharma organizations can prevent data integration hence data understanding; and there are many initiatives currently to make data more FAIR (Findable, Accessible, Interoperable, and Reusable)* and hence ensure value can be obtained. In addition, as with any analytical technology, the quality of the underlying data is critical. Flawed input data will produce flawed outputs (or, “garbage in, garbage out”). So, in order to leverage data effectively for AI and ML, it has to be clean.

    Within both our healthcare and pharma customers, Linguamatics NLP software is used to extract and clean data features from literature, clinical trial reports, electronic health records, in order to feed machine learning models. Use cases include using NLP in machine learning models to predict the risk of opioid medication abuse, identify gout flares to provide better patient control, or predict success or failure of novel therapeutics in clinical trials. 

    * A publication in 2016 introduced FAIR; https://www.nature.com/articles/sdata201618



     
    Jane Z. Reed, Ph.D. is Linguamatics’ head of life science strategy and responsible for developing the strategic vision for Linguamatics’ growing product portfolio and business development in the life science market.
    Related Searches
    • business development
    • Biopharma
    • roche
    • Phase I
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    Adare Pharma Solutions Adare Pharma Solutions
    Contracting And Outsourcing Agenda Contracting And Outsourcing Agenda
    Pfizer, GSK Form Consumer Healthcare JV Pfizer, GSK Form Consumer Healthcare JV
    AI in Pharma: Transforming Data into Drugs AI in Pharma: Transforming Data into Drugs
    Aileron, Pfizer in Clinical Collaboration Aileron, Pfizer in Clinical Collaboration
    Ology Bioservices Announces New SVP Ology Bioservices Announces New SVP
    Improving Pharma R&D Efficiency: The need to transform clinical trials Improving Pharma R&D Efficiency: The need to transform clinical trials
    Pfizer Names New CEO Pfizer Names New CEO
    Pfizer Signs $425m Flu Vaccine Deal with BioNTech Pfizer Signs $425m Flu Vaccine Deal with BioNTech
    Antares Enters Development Agreement With Pfizer Antares Enters Development Agreement With Pfizer

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Evidence Suggests Potential Oral Benefits for Curcumin Extract
    Oleic Acid Possibly Implicated in MS Pathology
    NIH Study Compares Low-Fat, Plant-Based to Low-Carb, Animal-Based Diet
    Coatings World

    Latest Breaking News From Coatings World

    In Memoriam: CIN’s Honorary Chairman António Serrenho
    OQ Chemicals Announces Sales Control for US Oxo Intermediates
    APV Engineered Coatings Reflects on 2020
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Alleviant's Transcatheter Tech Obtains Breakthrough Status
    Signia Appoints New President
    At-Home COVID-19 Test Kits Boosts Disease Monitoring Capabilities
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    Humanigen, Emergent Enter Covid-19 Partnership
    Samsung Bioepis Opens New Headquarters
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Aura Introduces Customizable Hair Care
    Corpack Creates Custom Packaging for Marlies Möller Hair Care Line
    Fitglow Beauty Wins Makeup Category at Annual Dirty Thinker’s Choice Awards
    Happi

    Latest Breaking News From Happi

    Some Good News at Inter Parfums
    Professional Beauty Association Names New Executive Director
    Curcumin's Role in Oral Care
    Ink World

    Latest Breaking News From Ink World

    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    VPF launches deep-freeze adhesive
    ProMach strengthens flexible packaging business
    Gallus planning virtual event for March
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    osteolabs Closes Second Financing Round of Nearly 1.6 Million Euros
    First Patient Implanted With NEXXT MATRIXX SA Cervical Turn-Lock System
    Cretex Companies CEO Steps Down
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    Imec Technology Taking Off to Space
    North American Semiconductor Equipment Industry Posts December 2020 Billings

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login